Clinical trials: Neoplasms, Prostatic
Prostate Cancer, Urologic Cancer
The Man Van Project
National Health Service (NHS) England has commissioned The Royal Marsden Hospital NHS Foundation Trust to run a novel mobile clinical outreach service called 'Man Van' with the aim of enabling male patients' easy access to care…
- Conditions
- Prostate Cancer, Urologic Cancer, Urologic Diseases, Bladder Cancer
- Trial name
- MV (NCT06357416)
- Testing
- MV-POCT Sub-study, Main Man Van Group Sub-study (MV-Eco), MV-QualQ Sub-study
- Where
- United Kingdom
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Head and Neck Neoplasm, Prostatic Neoplasm
Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms
Phase 1 safety, pharmacokinetics, and pharmacodynamics trial of the focal adhesion kinase (FAK) inhibitor PF-00562271 in patients with positive Positron Emission Tomography [PET] scans due to advanced non-hematologic…
- Conditions
- Head and Neck Neoplasm, Prostatic Neoplasm, Pancreatic Neoplasm
- Trial name
- NCT00666926
- Testing
- PF00562271
- Where
- 4 sites in United States, Australia and 1 more
- Volunteers
- 99 people
- Sponsor
- Verastem, Inc.
Male Breast Carcinoma, Prostate Adenocarcinoma
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy in treating patients with breast cancer, non-small cell lung cancer, or prostate cancer that has spread to other parts of the…
- Conditions
- Male Breast Carcinoma, Prostate Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Non-Small Cell Lung Carcinoma
- Trial name
- NCT02206334
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- 78 sites in United States, Canada and 1 more
- Volunteers
- 42 people
- Sponsor
- NRG Oncology
Prostate Cancer, Erectile Dysfunction
Athermal Nerve-sparing During Robotic-assisted Radical Prostatectomy Using a Hemostatic Matrix.
The purpose of this study is to evaluate the use of a hemostatic gelatine-thrombin matrix during athermal nerve-sparing prostate resection compared to conventional hemostasis using electrocautery in patients with localized…
- Trial name
- AnPro (NCT01448798)
- Testing
- Application of a hemostatic gelatin-thrombin matrix, Use of mono- and bipolar electrocautery and surgical clips
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Prostate Cancer
Cancer DNA Detection in Blood and Urine
This study is being conducted to collect and analyze biospecimens (blood and urine) and clinical data from patients with prostate cancer as well as healthy volunteers to better understand the differences between cancer cells and…
- Trial name
- NCT02657863
- Testing
- Urine collection and blood draw
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer, mHSPC
Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer
The goal of this phase 3 clinical trial is to determine the clinical effectiveness and cost effectiveness of using lower doses of Androgen Receptor Pathway Inhibitors (ARPI) to treat patients with prostate cancer that has spread…
- Conditions
- Prostate Cancer, mHSPC, mCRPC
- Trial name
- ENHANCE (NCT07751133)
- Testing
- Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,500 people
- Sponsor
- University College, London
Castrate Resistant Prostate Cancer, NUT Carcinoma
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
- Conditions
- Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
- Trial name
- NCT05488548
- Testing
- EP31670
- Where
- 6 sites in United States
- Volunteers
- 75 people
- Sponsor
- Epigenetix, Inc.
Prostatic Neoplasms
Evaluation of MRI for Prostate Cancer
The objective of this study is to evaluate imaging quality and correlation with histopathology in prostate cancer.
- Trial name
- NCT00930748
- Testing
- MR imaging with endorectal coil, MRI with endo-rectal coil
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Sheba Medical Center
Patients With Suspected Prostate Cancer
Multicentric Comparative Prospective Study of the Benefits and Risks of Biopsy Prostate Using Transrectal or Transperineal Procedure for the Prostate Cancer Diagnostic
The performance of prostatic biopsies is an essential element to confirm the diagnosis of prostate cancer and to specify the characteristics of the tumor in terms of stage and grade.
- Trial name
- BIOPROSTABORD (NCT05763355)
- Testing
- Biopsy
- Where
- 2 sites in France
- Volunteers
- 101 people
- Sponsor
- Elsan
Hormone-refractory Prostate Cancer
Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel
This is a Phase II, non-randomized, open label study of ILX651 in patients with hormone-refractory prostate cancer previously treated with docetaxel.
- Trial name
- NCT00082134
- Testing
- ILX651
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
Prostate Cancer
Smart After-Care in Patients With Prostate Cancer
This study aims to examine whether Smart After-Care service (Internet-and mobile-based lifestyle intervention) has an effect on patients' satisfaction and clinical outcomes in patients with prostate cancer on androgen deprivation…
- Trial name
- NCT03264209
- Testing
- Smart After-Care (Mobile health)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Ji Youl Lee
Bladder Cancer, Benign Prostatic Hyperplasia
Intravesical Prostatic Protrusion Mimicking Urothelial Cell Carcinoma of the Bladder
In this study, investigators aim to determine the true positivity of bladder cancer identified in the bladder base, trigone or neck on ultrasonography (USG) in patients presenting with hematuria or lower urinary tract symptoms…
- Conditions
- Bladder Cancer, Benign Prostatic Hyperplasia, Hematuria
- Trial name
- NCT05077852
- Testing
- Urethrocystoscopy
- Where
- Turkey (Türkiye)
- Volunteers
- 194 people
- Sponsor
- Ankara Training and Research Hospital
Abiraterone Acetate, MCRPC (metastatic Castration-resistant Prostate Cancer)
Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC
Acetate abiraterone tablets (II) is a modified new drug launched in China, prepared using nanocrystal technology and supplemented with SNAC as an absorption enhancer, working together to promote the gastrointestinal absorption of…
- Trial name
- mCRPC (NCT06768255)
- Testing
- Abiraterone Acetate (II)+ prednisolone (5mg bid) +ADT, Abiraterone acetate 1000 mg + prednisolone (5mg bid) +ADT
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Ding-Wei Ye
Health-Related Quality Of Life
A Pilot Study of Remote Monitoring to Improve Health Related Quality of Life of Men Following Prostate Cancer Treatment.
The purpose of this study is to determine the feasibility of using digital technology and remote monitoring to track health-related measures in men following prostate cancer treatment.
- Trial name
- NCT03434535
- Testing
- Technology Intervention
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Johns Hopkins University
Prostatic Neoplasms, Prostate Cancer
Pilot Study of SBRT and CDX-1127 in Prostate Cancer
This study evaluates the combination of stereotactic body radiation therapy (SBRT) and CDX-1127 in subjects with castration resistant prostate cancer.
- Trial name
- Prostate-04 (NCT02284971)
- Testing
- CDX1127, SBRT
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- James Larner, MD
Prostate Cancer Recurrent, Prostate Cancer
Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Initial performance of Ga-68-P16-093 in prostate cancer patients including dosimetry and preliminary efficacy evaluation in BCR patients, and correlation of Ga-68-P16-093 uptake with tissue histopathology in intermediate to high…
- Trial name
- NCT03444844
- Testing
- Ga-68 P16-093 PET/CT scan
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Five Eleven Pharma, Inc.
Prostate Cancer, Adenocarcinoma of the Prostate
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Temsirolimus and vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving temsirolimus together with vorinostat may kill more tumor cells.
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT01174199
- Testing
- vorinostat, temsirolimus, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Roswell Park Cancer Institute
Malignant Neoplasm of Prostate
Single-Port Versus Multi-Port Robotic Radical Prostatectomy
The purpose of this study is to compare two different techniques to perform the standard of care surgery to treat prostate cancer. This surgery is called robotic radical prostatectomy.
- Trial name
- NCT04696263
- Testing
- Da Vinci ® Xi system - MP Robotic Radical Prostatectomy, Da Vinci ® SP system - SP Robotic Radical Prostatectomy
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Performance of Prostate MRI and Following Biopsy to Detect Prostate Cancer Recurrence After Focal Therapy
The management of localized prostate cancer remains controversial because of a risk of over diagnosis and over treatment. Focal therapy represents an approach to improve the therapeutic ratio of prostate cancer treatments.
- Trial name
- IRMProft (NCT04773821)
- Testing
- Targeted biopsies
- Where
- 11 sites in France
- Volunteers
- 260 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
This is a biomarker preselected, randomized, open-label, multicenter, phase II study in men with metastatic castration resistant prostate cancer (mCRPC).
- Conditions
- Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT03012321
- Testing
- Olaparib, Abiraterone Acetate, Prednisone
- Where
- 16 sites in United States
- Volunteers
- 70 people
- Sponsor
- Northwestern University